Payment overview · 2025
General Payments
$616.25
16 reported records · 10 companies
Healthcare provider profile · identity verified
Bruce Allen Pendley, MD
Allopathic & Osteopathic Physicians|Family Medicine · EAST RIDGE, TN · NPI 1881634483
Verified facts
What the public records show
CMS Open Payments records show Bruce Allen Pendley, MD received $616.25 in general payments during 2025 across 16 reported records.
Kerecis Limited accounted for 34.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kerecis Limited | Unresolved — no canonical attribution shown | $210.48 | 34.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $110.15 | 17.9% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $91.58 | 14.9% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $63.86 | 10.4% | 1 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $39.19 | 6.4% | 1 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $31.53 | 5.1% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $23.64 | 3.8% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $15.73 | 2.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.58 | 2.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.51 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $616.25 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $210.48 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $210.48 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $110.15 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $63.86 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $59.39 | 3 | 2025 |
Source payment records
|
|||||
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $39.19 | 1 | 2025 |
Source payment records
|
|||||
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $31.53 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1245 | 175 |
| Levothyroxine Sodium | Levothyroxine Sodium | 788 | 102 |
| Omeprazole | Omeprazole | 680 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 614 | 69 |
| Furosemide | Furosemide | 497 | 96 |
| Potassium Chloride | Potassium Chloride | 491 | 98 |
| Tamsulosin Hcl | Tamsulosin Hcl | 489 | 45 |
| Lisinopril | Lisinopril | 466 | 54 |
| Gabapentin | Gabapentin | 446 | 87 |
| Eliquis | Apixaban | 385 | 48 |
| Baclofen | Baclofen | 376 | 29 |
| Spironolactone | Spironolactone | 315 | 35 |
| Allopurinol | Allopurinol | 296 | 26 |
| Losartan Potassium | Losartan Potassium | 294 | 60 |
| Carvedilol | Carvedilol | 290 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 271 | 45 |
| Donepezil Hcl | Donepezil Hcl | 261 | 25 |
| Metformin Hcl | Metformin Hcl | 243 | 48 |
| Memantine Hcl | Memantine Hcl | 241 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 239 | 55 |
| Tramadol Hcl | Tramadol Hcl | 231 | 52 |
| Sertraline Hcl | Sertraline Hcl | 230 | 36 |
| Valsartan | Valsartan | 220 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 206 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 199 | 38 |
| Santyl | Collagenase Clostridium Hist. | 177 | 62 |
| Alprazolam | Alprazolam | 168 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 168 | 44 |
| Trazodone Hcl | Trazodone Hcl | 166 | 45 |
| Meloxicam | Meloxicam | 165 | 45 |
| Levetiracetam | Levetiracetam | 153 | 18 |
| Montelukast Sodium | Montelukast Sodium | 152 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 148 | 44 |
| Finasteride | Finasteride | 146 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 144 | 14 |
| Mirtazapine | Mirtazapine | 143 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 48 |
| Ropinirole Hcl | Ropinirole Hcl | 137 | suppressed |
| Jardiance | Empagliflozin | 136 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 127 | 28 |
| Xarelto | Rivaroxaban | 122 | 11 |
| Gemfibrozil | Gemfibrozil | 120 | 47 |
| Prednisone | Prednisone | 119 | 37 |
| Amiodarone Hcl | Amiodarone Hcl | 114 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 111 | 18 |
| Flecainide Acetate | Flecainide Acetate | 111 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 103 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 93 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 87 | 20 |
| Midodrine Hcl | Midodrine Hcl | 86 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 84 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 23 |
| Glimepiride | Glimepiride | 77 | 23 |
| Lorazepam | Lorazepam | 75 | 43 |
| Torsemide | Torsemide | 73 | 15 |
| Bumetanide | Bumetanide | 72 | 22 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 72 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 72 | 36 |
| Memantine Hcl Er | Memantine Hcl | 68 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 66 | 33 |
| Metformin Hcl Er | Metformin Hcl | 65 | suppressed |
| Simvastatin | Simvastatin | 65 | suppressed |
| Ezetimibe | Ezetimibe | 64 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 64 | 12 |
| Januvia | Sitagliptin Phosphate | 63 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 62 | suppressed |
| Estradiol | Estradiol | 60 | 12 |
| Buspirone Hcl | Buspirone Hcl | 59 | 23 |
| Lactulose | Lactulose | 59 | 22 |
| Methimazole | Methimazole | 57 | suppressed |
| Methocarbamol | Methocarbamol | 57 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 56 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 56 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | suppressed |
| Clonazepam | Clonazepam | 53 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 13 |
| Latanoprost | Latanoprost | 49 | suppressed |
| Bupropion Xl | Bupropion Hcl | 48 | 15 |
| Entresto | Sacubitril/Valsartan | 48 | suppressed |
| Metronidazole | Metronidazole | 48 | 22 |
| Solifenacin Succinate | Solifenacin Succinate | 47 | suppressed |
| Pregabalin | Pregabalin | 46 | 13 |
| Famotidine | Famotidine | 45 | 24 |
| Mupirocin | Mupirocin | 44 | 22 |
| Fluconazole | Fluconazole | 42 | 18 |
| Promethazine Hcl | Promethazine Hcl | 41 | 25 |
| Topiramate | Topiramate | 40 | suppressed |
| Calcitriol | Calcitriol | 39 | suppressed |
| Lidocaine | Lidocaine | 38 | 18 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 38 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 22 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | 16 |
| Ondansetron Odt | Ondansetron | 34 | 25 |
| Cephalexin | Cephalexin | 33 | 23 |
| Farxiga | Dapagliflozin Propanediol | 33 | 13 |
| Loperamide | Loperamide Hcl | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | 11 |
| Amoxicillin | Amoxicillin | 30 | 25 |
| Ozempic | Semaglutide | 30 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 28 | suppressed |
| Ursodiol | Ursodiol | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Sucralfate | Sucralfate | 26 | 12 |
| Clonidine Hcl | Clonidine Hcl | 25 | 14 |
| Phenobarbital | Phenobarbital | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Lubiprostone | Lubiprostone | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Pentoxifylline | Pentoxifylline | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Rivastigmine | Rivastigmine | 20 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 19 | suppressed |
| Azithromycin | Azithromycin | 19 | 17 |
| Digoxin | Digoxin | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Nystatin | Nystatin | 18 | 14 |
| Primidone | Primidone | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | 15 |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Nystop | Nystatin | 17 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Calcium Acetate | Calcium Acetate | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Nitroglycerin | Nitroglycerin | 15 | 15 |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | 11 |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Gvoke Hypopen 1-Pack | Glucagon | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $616.25 · 16 records | Kerecis Limited | Auvelity, CAPLYTA, DAXXIFY, INGREZZA, Kerecis GraftGuide, Kerecis SurgiClose, Ohtuvayre, QULIPTA, REXULTI, UBRELVY, XYOSTED, Zunveyl | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error